A mass spectrometry guided approach for the identification of novel vaccine candidates in gram-negative pathogens.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
22 11 2019
Historique:
received: 21 05 2019
accepted: 27 10 2019
entrez: 24 11 2019
pubmed: 24 11 2019
medline: 6 11 2020
Statut: epublish

Résumé

Vaccination is the most effective method to prevent infectious diseases. However, approaches to identify novel vaccine candidates are commonly laborious and protracted. While surface proteins are suitable vaccine candidates and can elicit antibacterial antibody responses, systematic approaches to define surfomes from gram-negatives have rarely been successful. Here we developed a combined discovery-driven mass spectrometry and computational strategy to identify bacterial vaccine candidates and validate their immunogenicity using a highly prevalent gram-negative pathogen, Helicobacter pylori, as a model organism. We efficiently isolated surface antigens by enzymatic cleavage, with a design of experiment based strategy to experimentally dissect cell surface-exposed from cytosolic proteins. From a total of 1,153 quantified bacterial proteins, we thereby identified 72 surface exposed antigens and further prioritized candidates by computational homology inference within and across species. We next tested candidate-specific immune responses. All candidates were recognized in sera from infected patients, and readily induced antibody responses after vaccination of mice. The candidate jhp_0775 induced specific B and T cell responses and significantly reduced colonization levels in mouse therapeutic vaccination studies. In infected humans, we further show that jhp_0775 is immunogenic and activates IFNγ secretion from peripheral CD4

Identifiants

pubmed: 31758014
doi: 10.1038/s41598-019-53493-8
pii: 10.1038/s41598-019-53493-8
pmc: PMC6874673
doi:

Substances chimiques

Antigens, Bacterial 0
Antigens, Surface 0
Bacterial Proteins 0
Bacterial Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17401

Références

Nucleic Acids Res. 2016 Jan 4;44(D1):D447-56
pubmed: 26527722
Proteomics. 2012 Mar;12(6):845-58
pubmed: 22539435
Bioinformatics. 2009 Jun 1;25(11):1422-3
pubmed: 19304878
Science. 2000 Mar 10;287(5459):1816-20
pubmed: 10710308
J Proteomics. 2014 Jan 31;97:164-76
pubmed: 23624344
Biotechnol Bioeng. 2003 Jan 20;81(2):178-86
pubmed: 12451554
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
J Microbiol Methods. 2009 Aug;78(2):131-5
pubmed: 19426766
J Proteomics. 2012 Feb 2;75(4):1454-62
pubmed: 22166745
J Proteome Res. 2003 Jan-Feb;2(1):59-67
pubmed: 12643544
Nat Rev Gastroenterol Hepatol. 2011 Mar;8(3):133-40
pubmed: 21304478
Gastroenterology. 2013 Mar;144(3):591-600
pubmed: 23232294
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Dec 1;910:2-13
pubmed: 22333438
Int J Med Microbiol. 2013 Dec;303(8):618-23
pubmed: 24103649
Nat Rev Microbiol. 2007 Jun;5(6):441-52
pubmed: 17505524
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Leukemia. 2018 Feb;32(2):510-519
pubmed: 28663580
Cell. 2015 Oct 22;163(3):712-23
pubmed: 26496610
J Immunol. 2009 Jun 1;182(11):7085-101
pubmed: 19454706
Mol Cell Proteomics. 2018 Jan;17(1):43-60
pubmed: 29162636
Vaccine. 2007 Mar 30;25(14):2591-8
pubmed: 17239498
Methods Mol Biol. 2018;1722:21-29
pubmed: 29264796
Mol Cell Proteomics. 2018 Mar;17(3):422-430
pubmed: 29222161
Mol Cell Proteomics. 2015 Jan;14(1):120-35
pubmed: 25363814
Vet Pathol. 2012 Jan;49(1):32-43
pubmed: 22135019
Proteomics. 2011 Aug;11(15):3154-68
pubmed: 21630461
Immunome Res. 2011;7(2):
pubmed: 25152768
Cell Host Microbe. 2011 Feb 17;9(2):158-65
pubmed: 21320698
Gastroenterology. 1997 Apr;112(4):1386-97
pubmed: 9098027
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Nature. 2015 Oct 15;526(7573):443-7
pubmed: 26322584
Mol Cell Proteomics. 2009 Jul;8(7):1728-37
pubmed: 19401597
J Proteome Res. 2018 May 4;17(5):1784-1793
pubmed: 29651847
J Biol Chem. 2002 Aug 2;277(31):27896-902
pubmed: 12023975
Curr Opin Infect Dis. 2017 Oct;30(5):489-497
pubmed: 28704226
Methods Mol Biol. 2018;1734:83-96
pubmed: 29288449
EBioMedicine. 2016 May;7:112-20
pubmed: 27322465
Vaccine. 2012 May 30;30 Suppl 2:B87-97
pubmed: 22607904
Nucleic Acids Res. 1997 Sep 1;25(17):3389-402
pubmed: 9254694
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Mol Cell Proteomics. 2018 Aug;17(8):1487-1501
pubmed: 29716987
F1000 Biol Rep. 2010 May 11;2:
pubmed: 20948798
JAMA. 2004 Jan 14;291(2):244-5
pubmed: 14722152

Auteurs

Daniel Hornburg (D)

Max-Planck-Institute for Biochemistry, Martinsried, Germany.
Stanford University, School of Medicine, San Francisco, USA.

Tobias Kruse (T)

Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.
ImevaX GmbH, Munich, Germany.

Florian Anderl (F)

Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.
ImevaX GmbH, Munich, Germany.

Christina Daschkin (C)

Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.

Raphaela P Semper (RP)

Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.
German Center for infection research, partner site Munich, Munich, Germany.

Kathrin Klar (K)

ImevaX GmbH, Munich, Germany.

Anna Guenther (A)

NMI Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany.

Raquel Mejías-Luque (R)

Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.
German Center for infection research, partner site Munich, Munich, Germany.

Nicole Schneiderhan-Marra (N)

NMI Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany.

Matthias Mann (M)

Max-Planck-Institute for Biochemistry, Martinsried, Germany.

Felix Meissner (F)

Max-Planck-Institute for Biochemistry, Martinsried, Germany. meissner@biochem.mpg.de.

Markus Gerhard (M)

Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany. markus.gerhard@tum.de.
ImevaX GmbH, Munich, Germany. markus.gerhard@tum.de.
German Center for infection research, partner site Munich, Munich, Germany. markus.gerhard@tum.de.

Articles similaires

Photosynthesis Ribulose-Bisphosphate Carboxylase Carbon Dioxide Molecular Dynamics Simulation Cyanobacteria
Humans Middle Aged Female Male Surveys and Questionnaires
Adolescent Child Female Humans Male

Classifications MeSH